Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P B Chapman

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Cytokines, Cellular & Molecular Therapy|January 21, 2000
Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cellsM L Nasi, P Lieberman, K J Busam, et al.
The Journal of Biological Chemistry|February 20, 1999
The role of homophilic binding in anti-tumor antibody R24 recognition of molecular surfaces. Demonstration of an intermolecular beta-sheet interaction between vh domainsM J Kaminski, C R MacKenzie, M J Mooibroek, et al.
Blood|January 1, 1994
Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-alpha and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanomaL M Minasian, T P Szatrowski, M Rosenblum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696J M Kirkwood, J Ibrahim, D H Lawson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patientsM V Dhodapkar, J W Young, P B Chapman, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 15, 1987
Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 gangliosideK Welte, G Miller, P B Chapman, et al.
Cancer Research|December 1, 1990
Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanomaD F Bajorin, P B Chapman, G Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2000
Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response studyP B Chapman, D M Morrissey, K S Panageas, et al.
Investigational New Drugs|September 1, 1988
A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinomaP B Chapman, J E Kolitz, T B Hakes, et al.
International Journal of Cancer|July 18, 2000
Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptideJ J Lewis, S Janetzki, S Schaed, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Cytokines, Cellular & Molecular Therapy|January 21, 2000
Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cellsM L Nasi, P Lieberman, K J Busam, et al.
The Journal of Biological Chemistry|February 20, 1999
The role of homophilic binding in anti-tumor antibody R24 recognition of molecular surfaces. Demonstration of an intermolecular beta-sheet interaction between vh domainsM J Kaminski, C R MacKenzie, M J Mooibroek, et al.
Blood|January 1, 1994
Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-alpha and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanomaL M Minasian, T P Szatrowski, M Rosenblum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696J M Kirkwood, J Ibrahim, D H Lawson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patientsM V Dhodapkar, J W Young, P B Chapman, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 15, 1987
Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 gangliosideK Welte, G Miller, P B Chapman, et al.
Cancer Research|December 1, 1990
Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanomaD F Bajorin, P B Chapman, G Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2000
Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response studyP B Chapman, D M Morrissey, K S Panageas, et al.
Investigational New Drugs|September 1, 1988
A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinomaP B Chapman, J E Kolitz, T B Hakes, et al.
International Journal of Cancer|July 18, 2000
Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptideJ J Lewis, S Janetzki, S Schaed, et al.
Pageof 5